We are live on ! Find out more
EUCRU

Eucrates Biomedical Acquisition Corp. Unit
EUCRU

Delisted

EUCRU was delisted on the 26th of April, 2023.

Back to rankings

23 hedge funds and large institutions have $50.9M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 6 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

38% less funds holding

Funds holding: 37 → 23 (-14)

44% less capital invested

Capital invested by funds: $90.4M → $50.9M (-$39.5M)

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

78% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 18

Holders
23
Holders Change
-14
Holders Change %
-37.84%
% of All Funds
0.4%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
4
Increased
2
Reduced
6
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Verition Fund Management
Verition Fund Management
Connecticut
+$4.24M
2
HM
HealthCor Management
New York
+$3.56M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$216K
4
Morgan Stanley
Morgan Stanley
New York
+$41.5K
5
CCM
Condor Capital Management
New Jersey
+$27.7K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$9.86M
2
6CM
683 Capital Management
New York
-$6.4M
3
CH
CVI Holdings
Delaware
-$3.78M
4
MIM
Monashee Investment Management
Massachusetts
-$3.2M
5
SSA
Schonfeld Strategic Advisors
New York
-$3.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
CH
26
CVI Holdings
Delaware
– -$3.78M -355,000 Closed
MIM
27
Monashee Investment Management
Massachusetts
– -$3.2M -300,000 Closed
SSA
28
Schonfeld Strategic Advisors
New York
– -$3.2M -300,000 Closed
EC
29
EcoR1 Capital
California
– -$2.13M -200,000 Closed
LIM
30
Longfellow Investment Management
Massachusetts
– -$2.14M -200,000 Closed
ECM
31
Endurant Capital Management
California
– -$2.08M -195,000 Closed
HP
32
Hound Partners
New York
– -$1.87M -175,000 Closed
CC
33
Centiva Capital
New York
– -$1.65M -154,665 Closed
HI
34
HBK Investments
Texas
– -$1.6M -150,000 Closed
AA
35
AQR Arbitrage
Connecticut
– -$1.43M -137,500 Closed
RCM
36
Rivernorth Capital Management
Florida
– -$1.07M -100,000 Closed
Jane Street
37
Jane Street
New York
– -$853K -80,000 Closed
BFM
38
Boothbay Fund Management
New York
– -$752K -70,571 Closed
EAM
39
Exos Asset Management
New York
– -$112K -10,486 Closed
LCM
40
Landscape Capital Management
New Jersey
– -$107K -10,000 Closed
Royal Bank of Canada
41
Royal Bank of Canada
Ontario, Canada
– -$11K -1,000 Closed
1
2

EUCRU Hedge Fund Activity: Q1 2021 in Review

23 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q1 2021, worth a combined $50.9M — down 44% from $90.4M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of EUCRU and 4 opened new positions — a net loss of 14 holders — while 6 trimmed existing stakes and 2 added.

The largest buyer was Verition Fund Management, opening a new position worth an estimated $4.24M. The largest seller was BlackRock, exiting entirely with an estimated $9.86M sold.

  • 23 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q1 2021, down from 37 in Q4 2020.
  • Funds reported $50.9M of Eucrates Biomedical Acquisition Corp. Unit stock for Q1 2021, down 44% quarter-over-quarter.
  • 4 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q1 2021 and 18 closed out, a net change of -14 holders.
  • The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q1 2021 was Verition Fund Management, an estimated $4.24M added.
  • The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q1 2021 was BlackRock, an estimated $9.86M sold.

Based on aggregated 13F filings for Q1 2021.